Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 560-575

  Wurdinger, Thomas ^a,b   Deumelandt, Katrin ^b   van der Vliet, Hans J ^b   Wesseling, Pieter ^b,c   de Gruijl, Tanja D ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cross talk; Glioblastoma; Glioma associated macrophages and microglia; Immune response; Monocytes; Myeloid derived suppressor cells

Indexed keywords

ARGINASE 1; BEVACIZUMAB; CD163 ANTIGEN; CD200 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH DIFFERENTIATION FACTOR 15; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; STAT1 PROTEIN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIGEN PRESENTING CELL; BONE MARROW CELL; CANCER INFILTRATION; CANCER INHIBITION; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CELL MEMBRANE DEPOLARIZATION; CELL PHAGOCYTOSIS; CELL PROLIFERATION; CYTOKINE RELEASE; DOWN REGULATION; EMBRYO DEVELOPMENT; GLIOBLASTOMA; GLIOMA ASSOCIATED MICROGLIA AND MACROPHAGE; GLIOMA CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; MOLECULAR INTERACTION; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; PHAGOCYTOSIS; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; BRAIN NEOPLASMS; CELL COMMUNICATION; GLIOMA; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN NEOPLASMS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; GLIOMA; HUMANS; IMMUNE TOLERANCE; MYELOID CELLS; TUMOR MICROENVIRONMENT;

EID: 84921918767     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.10.003     Document Type: Review

References (247)

1. Holland E.C. Glioblastoma multiforme: The terminator. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6242-6244.
2. Ohgaki H., Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. (Berl.) 2005, 109:93-108. 10.1007/s00401-005-0991-y.
3. Johnson D.R., O'Neill B.P. Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol. 2012, 107:359-364. 10.1007/s11060-011-0749-4.
4. Provenge Official FDA information, side effects and uses (n.d.), (accessed January 7, 2014). http://www.drugs.com/pro/provenge.html.
5. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363:411-422. 10.1056/NEJMoa1001294.
6. Parney I.F.M.D., Hao C.M.D., Petruk K.C.M.D. Glioma immunology and immunotherapy. Neurosurgery 2000, 46:778-792. (April 2000).
7. Mitchell D.A., Fecci P.E., Sampson J.H. Immunotherapy of malignant brain tumors. Immunol. Rev. 2008, 222:70-100. 10.1111/j.1600-065X.2008.00603.x.
8. Grauer O.M., Wesseling P., Adema G.J. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol. 2009, 19:674-693. 10.1111/j.1750-3639.2009.00315.x.
9. Finocchiaro G., Pellegatta S. Immunotherapy for glioma: getting closer to the clinical arena?. [Miscellaneous Article]. Curr. Opin. Neurol. 2011, 24:641-647. (Dec. 2011). 10.1097/WCO.0b013e32834cbb17.
10. Saris S.C., Spiess P., Lieberman D.M., Lin S., Walbridge S., Oldfield E.H. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J. Neurosurg. 1992, 76:513-519. 10.3171/jns.1992.76.3.0513.
11. Jereb B., Petric-Grabnar G., Klun B., Lamovec J., Skrbec M., Soos E. Addition of IFN-alpha to treatment of malignant brain tumors. Acta Oncol. 1994, 33:651-654.
12. Mahaley M.S., Bigner D.D., Dudka L.F., Wilds P.R., Williams D.H., Bouldin T.W., et al. Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. J. Neurosurg. 1983, 59:201-207. 10.3171/jns.1983.59.2.0201.
13. Medawar P.B. Immunity to homologous grafted skin. III. The fate of skin homographs transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 1948, 29:58-69.
14. Barker C.F., Billingham R.E. Immunologically privileged sites. Adv. Immunol. 1977, 25:1-54.
15. Carson M.J., Doose J.M., Melchior B., Schmid C.D., Ploix C.C. CNS immune privilege: hiding in plain sight. Immunol. Rev. 2006, 213:48-65. 10.1111/j.1600-065X.2006.00441.x.
16. Galea I., Bechmann I., Perry V.H. What is immune privilege (not)?. Trends Immunol. 2007, 28:12-18. 10.1016/j.it.2006.11.004.
17. Parney I.F. Basic concepts in glioma immunology. Adv. Exp. Med. Biol. 2012, 746:42-52. 10.1007/978-1-4614-3146-6_4.
18. Rolle C.E., Sengupta S., Lesniak M.S. Mechanisms of immune evasion by gliomas. Glioma 2012, 53-76. Springer, New York, (http://link.springer.com/chapter/10.1007/978-1-4614-3146-6_5). R.Y. MD (Ed.).
19. Mehling M., Simon P., Mittelbronn M., Meyermann R., Ferrone S., Weller M., et al. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?. Acta Neuropathol. (Berl.) 2007, 114:111-119. 10.1007/s00401-007-0231-8.
20. Rossi M.L., Esiri M.M., Jones N.R., Coakham H.B., Moss T.H., Cruz-Sanchez F.F., et al. Characterization of the mononuclear cell infiltrate and HLA-Dr expression in 19 oligodendrogliomas. Surg. Neurol. 1991, 36:119-125.
21. Rebmann V., Regel J., Stolke D., Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin. Cancer Biol. 2003, 13:371-377.
22. Wiendl H., Mitsdoerffer M., Hofmeister V., Wischhusen J., Bornemann A., Meyermann R., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 2002, 168:4772-4780.
23. Tada T., Yabu K., Kobayashi S. Detection of active form of transforming growth factor-beta in cerebrospinal fluid of patients with glioma. Jpn. J. Cancer Res. Gann 1993, 84:544-548.
24. Shono T., Tofilon P.J., Bruner J.M., Owolabi O., Lang F.F. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001, 61:4375-4381.
25. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631. 10.1038/nrc2444.
26. Huettner C., Czub S., Kerkau S., Roggendorf W., Tonn J.C. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res. 1997, 17:3217-3224.
27. Zhang J., Sarkar S., Cua R., Zhou Y., Hader W., Yong V.W. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 2012, 33:312-319. 10.1093/carcin/bgr289.
28. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6:24-37. 10.1038/nrc1782.
29. Fuller G.N., Scheithauer B.W. The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol. 2007, 17:304-307. 10.1111/j.1750-3639.2007.00084.x.
30. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. (Berl.) 2007, 114:97-109. 10.1007/s00401-007-0243-4.
31. Burnet N.G., Jefferies S.J., Benson R.J., Hunt D.P., Treasure F.P. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br. J. Cancer 2005, 92:241-245. 10.1038/sj.bjc.6602321.
32. Claes A., Idema A.J., Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. (Berl.) 2007, 114:443-458. 10.1007/s00401-007-0293-7.
33. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
34. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013.
35. Verhaak R.G.W., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. 10.1016/j.ccr.2009.12.020.
36. Pagès F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 2009, 27:5944-5951. 10.1200/JCO.2008.19.6147.
37. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139.
38. Galon J., Pagès F., Marincola F.M., Thurin M., Trinchieri G., Fox B.A., et al. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 2012, 10:1. 10.1186/1479-5876-10-1.
39. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., et al. Towards the introduction of the "Immunoscore" in the classification of malignant tumours. J. Pathol. 2014, 232:199-209. 10.1002/path.4287.
40. Kmiecik J., Poli A., Brons N.H.C., Waha A., Eide G.E., Enger P.Ø., et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J. Neuroimmunol. 2013, 264:71-83. 10.1016/j.jneuroim.2013.08.013.
41. Badie B., Schartner J.M. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 2000, 46:957-961. (discussion 961-962).
42. Roggendorf W., Strupp S., Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. (Berl.) 1996, 92:288-293.
43. Prosniak M., Harshyne L.A., Andrews D.W., Kenyon L.C., Bedelbaeva K., Apanasovich T.V., et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin. Cancer Res. 2013, 19:3776-3786. 10.1158/1078-0432.CCR-12-1940.
44. Bhat K.P.L., Balasubramaniyan V., Vaillant B., Ezhilarasan R., Hummelink K., Hollingsworth F., et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 2013, 24:331-346. 10.1016/j.ccr.2013.08.001.
45. Ahmed Z., Shaw G., Sharma V.P., Yang C., McGowan E., Dickson D.W. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J. Histochem. Cytochem. 2007, 55:687-700. 10.1369/jhc.6A7156.2007.
46. Hoek R.M., Ruuls S.R., Murphy C.A., Wright G.J., Goddard R., Zurawski S.M., et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290:1768-1771.
47. Wei J., Gabrusiewicz K., Heimberger A. The controversial role of microglia in malignant gliomas. Clin. Dev. Immunol. 2013, 2013. 10.1155/2013/285246.
48. Ford A.L., Goodsall A.L., Hickey W.F., Sedgwick J.D. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J. Immunol. 1995, 154:4309-4321.
49. Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845. 10.1126/science.1194637.
50. Fu R., Shen Q., Xu P., Luo J.J., Tang Y. Phagocytosis of microglia in the central nervous system diseases. Mol. Neurobiol. 2014, 49:1422-1434. 10.1007/s12035-013-8620-6.
51. Perry V.H., Nicoll J.A.R., Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:193-201. 10.1038/nrneurol.2010.17.
52. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004, 173:3916-3924.
53. Hussain S.F., Yang D., Suki D., Aldape K., Grimm E., Heimberger A.B. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology 2006, 8:261-279. 10.1215/15228517-2006-008.
54. Rodrigues J.C., Gonzalez G.C., Zhang L., Ibrahim G., Kelly J.J., Gustafson M.P., et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology 2010, 12:351-365. 10.1093/neuonc/nop023.
55. Varvel N.H., Grathwohl S.A., Baumann F., Liebig C., Bosch A., Brawek B., et al. Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:18150-18155. 10.1073/pnas.1210150109.
56. Kennedy B.C., Showers C.R., Anderson D.E., Anderson L., Canoll P., Bruce J.N., et al. Tumor-associated macrophages in glioma: Friend or foe?. J. Oncol. 2013, 2013. 10.1155/2013/486912.
57. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2491-2496. 10.1073/pnas.1113744109.
58. Raychaudhuri B., Rayman P., Ireland J., Ko J., Rini B., Borden E.C., et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology 2011, 13:591-599. 10.1093/neuonc/nor042.
59. Raychaudhuri B., Vogelbaum M.A. The RCAS/TV - a model of murine glioma reproduces immunosuppression produced by myeloid-derived suppressor cells in humans with GBM. Neuro-Oncology 2011, 13:iii30-iii33. 10.1093/neuonc/nor150.
60. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506. 10.4049/jimmunol.0802740.
61. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 2010, 22:238-244. 10.1016/j.coi.2010.01.021.
62. Youn J.-I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
63. Dietlin T.A., Hofman F.M., Lund B.T., Gilmore W., Stohlman S.A., van der Veen R.C. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J. Leukoc. Biol. 2007, 81:1205-1212. 10.1189/jlb.1006640.
64. Källberg E., Stenström M., Liberg D., Ivars F., Leanderson T. CD11b+Ly6C++Ly6G- cells show distinct function in mice with chronic inflammation or tumor burden. BMC Immunol. 2012, 13:69. 10.1186/1471-2172-13-69.
65. Yi H., Guo C., Yu X., Zuo D., Wang X.-Y. Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J. Immunol. 2012, 189:4295-4304. 10.4049/jimmunol.1200086.
66. Youn J.-I., Gabrilovich D.I. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 2010, 40:2969-2975. 10.1002/eji.201040895.
67. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268. 10.1038/nri3175.
68. Cortez-Retamozo V., Engblom C., Pittet M.J. Remote control of macrophage production by cancer. Oncoimmunology 2013, 2:e24183. 10.4161/onci.24183.
69. Carvalho da Fonseca A.C., Badie B. Microglia and macrophages in malignant gliomas: Recent discoveries and implications for promising therapies. Clin. Dev. Immunol. 2013, 2013. 10.1155/2013/264124.
70. Platten M., Kretz A., Naumann U., Aulwurm S., Egashira K., Isenmann S., et al. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann. Neurol. 2003, 54:388-392. 10.1002/ana.10679.
71. Leung S.Y., Wong M.P., Chung L.P., Chan A.S., Yuen S.T. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol. (Berl.) 1997, 93:518-527.
72. Ku M.-C., Wolf S.A., Respondek D., Matyash V., Pohlmann A., Waiczies S., et al. GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis. Acta Neuropathol. (Berl.) 2013, 125:609-620. 10.1007/s00401-013-1079-8.
73. Badie B., Schartner J., Klaver J., Vorpahl J. In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Neurosurgery 1999, 44:1077-1082. (discussion 1082-1083).
74. Wang S.-C., Hong J.-H., Hsueh C., Chiang C.-S. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab. Invest. 2012, 92:151-162. 10.1038/labinvest.2011.128.
75. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272. 10.1038/nm.3337.
76. Villeneuve J., Tremblay P., Vallières L. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res. 2005, 65:3928-3936. 10.1158/0008-5472.CAN-04-3612.
77. Forstreuter F., Lucius R., Mentlein R. Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J. Neuroimmunol. 2002, 132:93-98.
78. Li W., Graeber M.B. The molecular profile of microglia under the influence of glioma. Neuro-Oncology 2012, 14:958-978. 10.1093/neuonc/nos116.
79. Sielska M., Przanowski P., Wylot B., Gabrusiewicz K., Maleszewska M., Kijewska M., et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J. Pathol. 2013, 230:310-321. 10.1002/path.4192.
80. Wang S.-C., Yu C.-F., Hong J.-H., Tsai C.-S., Chiang C.-S. Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLoS One 2013, 8:e69182. 10.1371/journal.pone.0069182.
81. Yi L., Xiao H., Xu M., Ye X., Hu J., Li F., et al. Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J. Neuroimmunol. 2011, 232:75-82. 10.1016/j.jneuroim.2010.10.011.
82. Wu A., Wei J., Kong L.-Y., Wang Y., Priebe W., Qiao W., et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology 2010, 12:1113-1125. 10.1093/neuonc/noq082.
83. Sarkar S., Döring A., Zemp F.J., Silva C., Lun X., Wang X., et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat. Neurosci. 2014, 17:46-55. 10.1038/nn.3597.
84. Gabrusiewicz K., Ellert-Miklaszewska A., Lipko M., Sielska M., Frankowska M., Kaminska B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One 2011, 6:e23902. 10.1371/journal.pone.0023902.
85. Olah M., Biber K., Vinet J., Boddeke H.W.G.M. Microglia phenotype diversity. CNS Neurol. Disord. Drug Targets 2011, 10:108-118.
86. Hanisch U.-K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394. 10.1038/nn1997.
87. Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216:15-24. 10.1002/path.2370.
88. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. J. Virtual Librar. 2008, 13:453-461.
89. Hao N.-B., Lü M.-H., Fan Y.-H., Cao Y.-L., Zhang Z.-R., Yang S.-M. Macrophages in tumor microenvironments and the progression of tumors. J. Immunol. Res. 2012, 2012. 10.1155/2012/948098.
90. Komohara Y., Horlad H., Ohnishi K., Ohta K., Makino K., Hondo H., et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J. Clin. Exp. Hematopathol. 2011, 51:93-99.
91. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 2011, 11:750-761. 10.1038/nri3088.
92. Komohara Y., Horlad H., Ohnishi K., Fujiwara Y., Bai B., Nakagawa T., et al. Importance of direct macrophage - Tumor cell interaction on progression of human glioma. Cancer Sci. 2012, 103:2165-2172. 10.1111/cas.12015.
93. Zhang L., Liu W., Alizadeh D., Zhao D., Farrukh O., Badie B. S100B attenuates microglia activation in gliomas: possible role for STAT3 pathway. Neuro-Oncology 2010, 12:iv29-iv32. 10.1093/neuonc/noq116.s4.
94. Tiemessen M.M., Jagger A.L., Evans H.G., van Herwijnen M.J.C., John S., Taams L.S. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19446-19451. 10.1073/pnas.0706832104.
95. Wong S.-C., Puaux A.-L., Chittezhath M., Shalova I., Kajiji T.S., Wang X., et al. Macrophage polarization to a unique phenotype driven by B cells. Eur. J. Immunol. 2010, 40:2296-2307. 10.1002/eji.200940288.
96. Squadrito M.L., Etzrodt M., De Palma M., Pittet M.J. MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol. 2013, 34:350-359. 10.1016/j.it.2013.02.003.
97. Etzrodt M., Cortez-Retamozo V., Newton A., Zhao J., Ng A., Wildgruber M., et al. Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep. 2012, 1:317-324. 10.1016/j.celrep.2012.02.009.
98. Pucci F., Pittet M.J. Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. Clin. Cancer Res. 2013, 19:2598-2604. 10.1158/1078-0432.CCR-12-0962.
99. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A.J., Hopmans E.S., Lindenberg J.L., et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6328-6333. 10.1073/pnas.0914843107.
100. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 2008, 10:619-624. 10.1038/ncb1725.
101. Zhang L., Alizadeh D., Van Handel M., Kortylewski M., Yu H., Badie B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 2009, 57:1458-1467. 10.1002/glia.20863.
102. Hishii M., Nitta T., Ishida H., Ebato M., Kurosu A., Yagita H., et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. [miscellaneous article]. Neurosurgery 1995, 37:1160-1167. (Dec. 1995).
103. Frei K., Lins H., Schwerdel C., Fontana A. Antigen presentation in the central nervous system. The inhibitory effect of IL-10 on MHC class II expression and production of cytokines depends on the inducing signals and the type of cell analyzed. J. Immunol. 1994, 152:2720-2728.
104. Woiciechowsky C., Asadullah K., Nestler D., Schöning B., Glöckner F., Döcke W.D., et al. Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J. Neuroimmunol. 1998, 84:164-171.
105. Kren L., Muckova K., Lzicarova E., Sova M., Vybihal V., Svoboda T., et al. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity?. J. Neuroimmunol. 2010, 220:131-135. 10.1016/j.jneuroim.2010.01.014.
106. Satoh J., Lee Y.B., Kim S.U. T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res. 1995, 704:92-96.
107. Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., et al. Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science 1999, 286:2352-2355. 10.1126/science.286.5448.2352.
108. Matyszak M.K., Denis-Donini S., Citterio S., Longhi R., Granucci F., Ricciardi-Castagnoli P. Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation. Eur. J. Immunol. 1999, 29:3063-3076. 10.1002/(SICI)1521-4141(199910)29:10<3063::AID-IMMU3063>3.0.CO;2-G.
109. Badie B., Schartner J., Prabakaran S., Paul J., Vorpahl J. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J. Neuroimmunol. 2001, 120:19-24.
110. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 2002, 195:1303-1316.
111. Bloch O., Crane C.A., Kaur R., Safaee M., Rutkowski M.J., Parsa A.T. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin. Cancer Res. 2013, 19:3165-3175. 10.1158/1078-0432.CCR-12-3314.
112. Conti A., Gulì C., La Torre D., Tomasello C., Angileri F.F., Aguennouz M. Role of inflammation and oxidative stress mediators in gliomas. Cancers 2010, 2:693-712. 10.3390/cancers2020693.
113. Nakano Y., Kuroda E., Kito T., Yokota A., Yamashita U. Induction of macrophagic prostaglandin E2 synthesis by glioma cells. J. Neurosurg. 2006, 104:574-582. 10.3171/jns.2006.104.4.574.
114. Kuppner M.C., Sawamura Y., Hamou M.F., de Tribolet N. Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes. J. Neurosurg. 1990, 72:619-625. 10.3171/jns.1990.72.4.0619.
115. Akasaki Y., Liu G., Chung N.H.C., Ehtesham M., Black K.L., Yu J.S. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 2004, 173:4352-4359.
116. Ebner F., Brandt C., Thiele P., Richter D., Schliesser U., Siffrin V., et al. Microglial activation milieu controls regulatory T cell responses. J. Immunol. 2013, 191:5594-5602. 10.4049/jimmunol.1203331.
117. Savage N.D.L., de Boer T., Walburg K.V., Joosten S.A., van Meijgaarden K., Geluk A., et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J. Immunol. 2008, 181:2220-2226.
118. Coniglio S.J., Segall J.E. Review: molecular mechanism of microglia stimulated glioblastoma invasion. Matrix Biol. 2013, 32:372-380. 10.1016/j.matbio.2013.07.008.
119. Markovic D.S., Vinnakota K., Chirasani S., Synowitz M., Raguet H., Stock K., et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12530-12535. 10.1073/pnas.0804273106.
120. Vinnakota K., Hu F., Ku M.-C., Georgieva P.B., Szulzewsky F., Pohlmann A., et al. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro-Oncology 2013, 15:1457-1468. 10.1093/neuonc/not115.
121. Konnecke H., Bechmann I. The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin. Dev. Immunol. 2013, 2013. 10.1155/2013/914104.
122. Esteve P.-O., Tremblay P., Houde M., St-Pierre Y., Mandeville R. In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. Biochim. Biophys. Acta BBA - Mol. Cell Res. 1998, 1403:85-96. 10.1016/S0167-4889(98)00020-2.
123. Held-Feindt J., Hattermann K., Müerköster S.S., Wedderkopp H., Knerlich-Lukoschus F., Ungefroren H., et al. CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp. Cell Res. 2010, 316:1553-1566. 10.1016/j.yexcr.2010.02.018.
124. da Fonseca A.C.C., Romão L., Amaral R.F., Assad Kahn S., Lobo D., Martins S., et al. Microglial stress inducible protein 1 promotes proliferation and migration in human glioblastoma cells. Neuroscience 2012, 200:130-141. 10.1016/j.neuroscience.2011.10.025.
125. Ye X., Xu S., Xin Y., Yu S., Ping Y., Chen L., et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J. Immunol. 2012, 189:444-453. 10.4049/jimmunol.1103248.
126. Koochekpour S., Merzak A., Pilkington G.J. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett. 1996, 102:209-215.
127. Coniglio S.J., Eugenin E., Dobrenis K., Stanley E.R., West B.L., Symons M.H., et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol. Med. 2012, 18:519-527. 10.2119/molmed.2011.00217.
128. Lafuente J.V., Adán B., Alkiza K., Garibi J.M., Rossi M., Cruz-Sánchez F.F. Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J. Mol. Neurosci. 1999, 13:177-185. 10.1385/JMN:13:1-2:177.
129. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z., Wang J., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 2009, 124:2621-2633. 10.1002/ijc.24249.
130. Exosomes: Mediators of neurodegeneration, neuroprotection and therapeutics - Springer (n.d.), (accessed February 4, 2014). http://link.springer.com/article/10.1007%2Fs12035-013-8544-1/fulltext.html.
131. Kohanbash G., McKaveney K., Sakaki M., Ueda R., Mintz A.H., Amankulor N., et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res. 2013, 73:6413-6423. 10.1158/0008-5472.CAN-12-4124.
132. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16:53-65. 10.1016/j.semcancer.2005.07.005.
133. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 2004, 4:941-952. 10.1038/nri1498.
134. Lechner M.G., Liebertz D.J., Epstein A.L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 2010, 185:2273-2284. 10.4049/jimmunol.1000901.
135. Tchirkov A., Rolhion C., Bertrand S., Doré J.F., Dubost J.J., Verrelle P. IL-6 gene amplification and expression in human glioblastomas. Br. J. Cancer 2001, 85:518-522. 10.1054/bjoc.2001.1942.
136. Mueller M.M., Herold-Mende C.C., Riede D., Lange M., Steiner H.H., Fusenig N.E. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am. J. Pathol. 1999, 155:1557-1567. 10.1016/S0002-9440(10)65472-7.
137. Sasaki A., Tamura M., Hasegawa M., Ishiuchi S., Hirato J., Nakazato Y. Expression of interleukin-1beta mRNA and protein in human gliomas assessed by RT-PCR and immunohistochemistry. J. Neuropathol. Exp. Neurol. 1998, 57:653-663.
138. Berindan-Neagoe I., Chiorean R., Braicu C., Florian I.S., Leucuta D., Crisan D., et al. Quantitative mRNA expression of genes involved in angiogenesis, coagulation and inflammation in multiforme glioblastoma tumoral tissue versus peritumoral brain tissue: lack of correlation with clinical data. Eur. Cytokine Netw. 2012, 23:45-55. 10.1684/ecn.2012.0302.
139. Verschuere T., Toelen J., Maes W., Poirier F., Boon L., Tousseyn T., et al. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int. J. Cancer 2014, 134:873-884. 10.1002/ijc.28426.
140. Varga G., Ehrchen J., Tsianakas A., Tenbrock K., Rattenholl A., Seeliger S., et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J. Leukoc. Biol. 2008, 84:644-650. 10.1189/jlb.1107768.
141. Oosterhoff D., Lougheed S., van de Ven R., Lindenberg J., van Cruijsen H., Hiddingh L., et al. Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology 2012, 1:649-658. 10.4161/onci.20365.
142. van Cruijsen H., Oosterhoff D., Lindenberg J.J., Lougheed S.M., Fehres C., Weijers K., et al. Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. Immunotherapy 2011, 3:1051-1061. 10.2217/imt.11.107.
143. Sombroek C.C., Stam A.G.M., Masterson A.J., Lougheed S.M., Schakel M.J.A.G., Meijer C.J.L.M., et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 2002, 168:4333-4343.
144. Heusinkveld M., de Vos P.J., van Steenwijk R., Goedemans T.H., Ramwadhdoebe A., Gorter M.J.P.Welters, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 2011, 187:1157-1165. 10.4049/jimmunol.1100889.
145. Obermajer N., Muthuswamy R., Lesnock J., Edwards R.P., Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011, 118:5498-5505. 10.1182/blood-2011-07-365825.
146. Fujita M., Kohanbash G., McDonald H.A., Delamarre L., Decker S.A., Ohlfest J.R., et al. Cox2 blockade suppresses gliomagenesis by inhibiting CCL2-mediated accumulation of myeloid-derived suppressor cells in glioma sites. Neuro-Oncology 2010, 12:iv32-iv36. 10.1093/neuonc/noq116.s5.
147. Fujita M., Kohanbash G., Fellows-Mayle W., Hamilton R.L., Komohara Y., Decker S.A., et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011, 71:2664-2674. 10.1158/0008-5472.CAN-10-3055.
148. Jia W., Jackson-Cook C., Graf M.R. Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma+vaccination model. J. Neuroimmunol. 2010, 223:20-30. 10.1016/j.jneuroim.2010.03.011.
149. Nagaraj S., Gabrilovich D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008, 68:2561-2563. 10.1158/0008-5472.CAN-07-6229.
150. Rodriguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 2008, 222:180-191. 10.1111/j.1600-065X.2008.00608.x.
151. Sippel T.R., White J., Nag K., Tsvankin V., Klaassen M., Kleinschmidt-DeMasters B.K., et al. Neutrophil degranulation and immunosuppression in patients with GBM: Restoration of cellular immune function by targeting arginase I. Clin. Cancer Res. 2011, 17:6992-7002. 10.1158/1078-0432.CCR-11-1107.
152. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189:1363-1372.
153. Fallarino F., Grohmann U., Vacca C., Orabona C., Spreca A., Fioretti M.C., et al. T cell apoptosis by kynurenines. Adv. Exp. Med. Biol. 2003, 527:183-190.
154. Fallarino F., Grohmann U. Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr. Med. Chem. 2011, 18:2215-2221.
155. Huang B., Pan P.-Y., Li Q., Sato A.I., Levy D.E., Bromberg J., et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131. 10.1158/0008-5472.CAN-05-1299.
156. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008, 68:5439-5449. 10.1158/0008-5472.CAN-07-6621.
157. Vandenberk L., Van Gool S.W. Treg infiltration in glioma: a hurdle for antiglioma immunotherapy. Immunotherapy 2012, 4:675-678. 10.2217/imt.12.64.
158. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35. 10.1016/j.ccr.2007.12.004.
159. Paladugu M., Thakur A., Lum L.G., Mittal S., Parajuli P. Generation and immunologic functions of Th17 cells in malignant gliomas. Cancer Immunol. Immunother. 2013, 62:75-86. 10.1007/s00262-012-1312-7.
160. Hoechst B., Gamrekelashvili J., Manns M.P., Greten T.F., Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011, 117:6532-6541. 10.1182/blood-2010-11-317321.
161. Piao Y., Liang J., Holmes L., Zurita A.J., Henry V., Heymach J.V., et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncology 2012, 14:1379-1392. 10.1093/neuonc/nos158.
162. A.Q., N.T., Ge L., Arismendi G., Paleo B., E.J., et al. Using REMBRANDT to paint in the details of glioma biology: Applications for future immunotherapy. Evol. Mol. Biol. Brain Tumors Ther. Implic 2013, InTech, (http://www.intechopen.com/books/howtoreference/evolution-of-the-molecular-biology-of-brain-tumors-and-the-therapeutic-implications/using-rembrandt-to-paint-in-the-details-of-glioma-biology-applications-for-future-immunotherapy (accessed January 28, 2014)). T. Lichtor (Ed.).
163. Umemura N., Saio M., Suwa T., Kitoh Y., Bai J., Nonaka K., et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol. 2008, 83:1136-1144. 10.1189/jlb.0907611.
164. Hu X., Li B., Li X., Zhao X., Wan L., Lin G., et al. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J. Immunol. 2014, 192:1320-1331. 10.4049/jimmunol.1203195.
165. Ye X.-Z., Yu S.-C., Bian X.-W. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J. Genet. Genomics 2010, 37:423-430. 10.1016/S1673-8527(09)60061-8.
166. Patel S., Wetie A.G.N., Darie C.C., Clarkson B.D. Cancer secretomes and their place in supplementing other hallmarks of cancer. Adv. Exp. Med. Biol. 2014, 806:409-442. 10.1007/978-3-319-06068-2_20.
167. Skog J., Würdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10:1470-1476. 10.1038/ncb1800.
168. Bobrie A., Krumeich S., Reyal F., Recchi C., Moita L.F., Seabra M.C., et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 2012, 72:4920-4930. 10.1158/0008-5472.CAN-12-0925.
169. Deng Z., Cheng Z., Xiang X., Yan J., Zhuang X., Liu C., et al. Tumor cell cross talk with tumor-associated leukocytes leads to induction of tumor exosomal fibronectin and promotes tumor progression. Am. J. Pathol. 2012, 180:390-398. 10.1016/j.ajpath.2011.09.023.
170. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659. 10.1038/ncb1596.
171. Chistiakov D.A., Chekhonin V.P. Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. Tumor Biol. 2014, 1-14. 10.1007/s13277-014-2262-9.
172. Kore R.A., Abraham E.C. Inflammatory cytokines, interleukin-1 beta and tumor necrosis factor-alpha, upregulated in glioblastoma multiforme, raise the levels of CRYAB in exosomes secreted by U373 glioma cells. Biochem. Biophys. Res. Commun. 2014, 10.1016/j.bbrc.2014.09.068.
173. Kros J.M., Mustafa D.M., Dekker L.J.M., Sillevis Smitt P.A.E., Luider T.M., Zheng P.-P. Circulating glioma biomarkers. Neuro-Oncology 2014, 10.1093/neuonc/nou207.
174. Santiago-Dieppa D.R., Steinberg J., Gonda D., Cheung V.J., Carter B.S., Chen C.C. Extracellular vesicles as a platform for "liquid biopsy" in glioblastoma patients. Expert Rev. Mol. Diagn. 2014, 14:819-825. 10.1586/14737159.2014.943193.
175. Christianson H.C., Svensson K.J., van Kuppevelt T.H., Li J.-P., Belting M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17380-17385. 10.1073/pnas.1304266110.
176. Svensson K.J., Christianson H.C., Wittrup A., Bourseau-Guilmain E., Lindqvist E., Svensson L.M., et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. J. Biol. Chem. 2013, 288:17713-17724. 10.1074/jbc.M112.445403.
177. Kucharzewska P., Christianson H.C., Welch J.E., Svensson K.J., Fredlund E., Ringner M., et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7312-7317. 10.1073/pnas.1220998110.
178. Garnier D., Jabado N., Rak J. Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. Proteomics 2013, 13:1595-1607. 10.1002/pmic.201200360.
179. Montecalvo A., Larregina A.T., Shufesky W.J., Stolz D.B., Sullivan M.L.G., Karlsson J.M., et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012, 119:756-766. 10.1182/blood-2011-02-338004.
180. Parolini I., Federici C., Raggi C., Lugini L., Palleschi S., De Milito A., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 2009, 284:34211-34222. 10.1074/jbc.M109.041152.
181. Tian T., Wang Y., Wang H., Zhu Z., Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. J. Cell. Biochem. 2010, 111:488-496. 10.1002/jcb.22733.
182. Atai N.A., Balaj L., van Veen H., Breakefield X.O., Jarzyna P.A., Van Noorden C.J.F., et al. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. J. Neurooncol. 2013, 115:343-351. 10.1007/s11060-013-1235-y.
183. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S., et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008, 15:80-88. 10.1038/sj.cdd.4402237.
184. Cossetti C., Smith J.A., Iraci N., Leonardi T., Pluchino S. Extracellular membrane vesicles and immune regulation in the brain. Front. Membr. Physiol. Membr. Biophys. 2012, 3:117. 10.3389/fphys.2012.00117.
185. Anand P.K. Exosomal membrane molecules are potent immune response modulators. Commun. Integr. Biol. 2010, 3:405-408. 10.4161/cib.3.5.12474.
186. de Vrij J., Kwappenberg K.M.C., Maas S.L.N., Kleijn A., Lamfers M.L., Dirven C.M.F., et al. Immune-modulatory properties of glioblastoma multiforme exosomes. Neuro-Oncology 2011, 13:iii30-iii33. 10.1093/neuonc/nor150.
187. Sabin K.Z., Lebert D., Thibado V., Rovin R., Lawrence J., Winn R. Glioblastoma-derived exosomes contribute to tumor immune evasion. Neuro-Oncology 2011, 13:iii30-iii33. 10.1093/neuonc/nor150.
188. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.-P., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457-471. 10.1172/JCI40483.
189. Burke M., Choksawangkarn W., Edwards N., Ostrand-Rosenberg S., Fenselau C. Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J. Proteome Res. 2014, 13:836-843. 10.1021/pr400879c.
190. Burke M., Choksawangkarn W., Edwards N., Ostrand-Rosenberg S., Fenselau C. Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J. Proteome Res. 2013, 10.1021/pr400879c.
191. Yang M., Chen J., Su F., Yu B., Su F., Lin L., et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 2011, 10:117. 10.1186/1476-4598-10-117.
192. Jethwa K., Wei J., McEnery K., Heimberger A.B. miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin. Invest. 2011, 1:1637-1650. 10.4155/cli.11.159.
193. Suzuki H.I., Katsura A., Matsuyama H., Miyazono K. MicroRNA regulons in tumor microenvironment. Oncogene 2014, 10.1038/onc.2014.254.
194. Katakowski M., Buller B., Zheng X., Lu Y., Rogers T., Osobamiro O., et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013, 335:201-204. 10.1016/j.canlet.2013.02.019.
195. Bronisz A., Wang Y., Nowicki M.O., Peruzzi P., Ansari K.I., Ogawa D., et al. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res. 2014, 74:738-750. 10.1158/0008-5472.CAN-13-2650.
196. Chevillet J.R., Kang Q., Ruf I.K., Briggs H.A., Vojtech L.N., Hughes S.M., et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc. Natl. Acad. Sci. 2014, 201408301. 10.1073/pnas.1408301111.
197. Koppers-Lalic D., Hackenberg M., Bijnsdorp I.V., van Eijndhoven M.A.J., Sadek P., Sie D., et al. Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. Cell Rep. 2014, 8:1649-1658. 10.1016/j.celrep.2014.08.027.
198. Li C.C., Eaton S.A., Young P.E., Lee M., Shuttleworth R., Humphreys D.T., et al. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. RNA Biol. 2013, 10:1333-1344. 10.4161/rna.25281.
199. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 2011, 21:139-146. 10.1016/j.semcancer.2011.01.002.
200. Peinado H., Alečković M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891. 10.1038/nm.2753.
201. Barcellos-Hoff M.H., Lyden D., Wang T.C. The evolution of the cancer niche during multistage carcinogenesis. Nat. Rev. Cancer 2013, 13:511-518. 10.1038/nrc3536.
202. Aliotta J.M., Pereira M., Johnson K.W., de Paz N., Dooner M.S., Puente N., et al. Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Exp. Hematol. 2010, 38:233-245. 10.1016/j.exphem.2010.01.002.
203. Aliotta J.M., Sanchez-Guijo F.M., Dooner G.J., Johnson K.W., Dooner M.S., Greer K.A., et al. Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. Stem Cells 2007, 25:2245-2256. 10.1634/stemcells. 2007-0128.
204. Nilsson R.J.A., Balaj L., Hulleman E., van Rijn S., Pegtel D.M., Walraven M., et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011, 118:3680-3683. 10.1182/blood-2011-03-344408.
205. Bastida E., Ordinas A., Escolar G., Jamieson G.A. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 1984, 64:177-184.
206. Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20:576-590. 10.1016/j.ccr.2011.09.009.
207. Setzer F., Oberle V., Bläss M., Möller E., Russwurm S., Deigner H.-P., et al. Platelet-derived microvesicles induce differential gene expression in monocytic cells: a DNA microarray study. Platelets 2006, 17:571-576. 10.1080/09537100600760244.
208. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11:123-134. 10.1038/nrc3004.
209. Aatonen M., Grönholm M., Siljander P.R.-M. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin. Thromb. Hemost. 2012, 38:102-113. 10.1055/s-0031-1300956.
210. Zaslavsky A., Baek K.-H., Lynch R.C., Short S., Grillo J., Folkman J., et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 2010, 115:4605-4613. 10.1182/blood-2009-09-242065.
211. Feng W., Madajka M., Kerr B.A., Mahabeleshwar G.H., Whiteheart S.W., Byzova T.V. A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing. Blood 2011, 117:3893-3902. 10.1182/blood-2010-08-304808.
212. Stellos K., Gawaz M. Platelets and stromal cell-derived factor-1 in progenitor cell recruitment. Semin. Thromb. Hemost. 2007, 33:159-164. 10.1055/s-2007-969029.
213. Kuznetsov H.S., Marsh T., Markens B.A., Castaño Z., Greene-Colozzi A., Hay S.A., et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov. 2012, 2:1150-1165. 10.1158/2159-8290.CD-12-0216.
214. Stone R.L., Nick A.M., McNeish I.A., Balkwill F., Han H.D., Bottsford-Miller J., et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 2012, 366:610-618. 10.1056/NEJMoa1110352.
215. Kesanakurti D., Chetty C., Dinh D.H., Gujrati M., Rao J.S. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma. Oncogene 2013, 32:327-340. 10.1038/onc.2012.52.
216. Janowska-Wieczorek A., Wysoczynski M., Kijowski J., Marquez-Curtis L., Machalinski B., Ratajczak J., et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 2005, 113:752-760. 10.1002/ijc.20657.
217. Huether G., Fettkötter I., Keilhoff G., Wolf G. Serotonin acts as a radical scavenger and is oxidized to a dimer during the respiratory burst of activated microglia. J. Neurochem. 1997, 69:2096-2101.
218. Rhodes K.E., Raivich G., Fawcett J.W. The injury response of oligodendrocyte precursor cells is induced by platelets, macrophages and inflammation-associated cytokines. Neuroscience 2006, 140:87-100. 10.1016/j.neuroscience.2006.01.055.
219. Brockmann M.A., Bender B., Plaxina E., Nolte I., Erber R., Lamszus K., et al. Differential effects of tumor-platelet interaction in vitro and in vivo in glioblastoma. J. Neurooncol. 2011, 105:45-56. 10.1007/s11060-011-0560-2.
220. Brockmann M.A., Giese A., Mueller K., Kaba F.J., Lohr F., Weiss C., et al. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro-Oncology 2007, 9:335-342. 10.1215/15228517-2007-013.
221. Williams M., Liu Z.W., Woolf D., Hargreaves S., Michalarea V., Menashy R., et al. Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. J. Cancer Res. Clin. Oncol. 2012, 138:1683-1688. 10.1007/s00432-012-1243-x.
222. Kennedy B.C., Maier L.M., D'Amico R., Mandigo C.E., Fontana E.J., Waziri A., et al. Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol. 2009, 10:11. 10.1186/1471-2172-10-11.
223. Voisin P., Bouchaud V., Merle M., Diolez P., Duffy L., Flint K., et al. Microglia in close vicinity of glioma cells: correlation between phenotype and metabolic alterations. Front. Neuroenerg. 2010, 2:131. 10.3389/fnene.2010.00131.
224. Kim Y.-S., Kim Y.-J., Lee J.-M., Kim E.-K., Park Y.-J., Choe S.-K., et al. Functional changes in myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs. J. Immunol. 2012, 188:4226-4234. 10.4049/jimmunol.1103040.
225. Palazón A., Aragonés J., Morales-Kastresana A., de Landázuri M.O., Melero I. Molecular pathways: Hypoxia response in immune cells fighting or promoting cancer. Clin. Cancer Res. 2012, 18:1207-1213. 10.1158/1078-0432.CCR-11-1591.
226. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.-I., Cheng P., et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207:2439-2453. 10.1084/jem.20100587.
227. Fadul C.E., Fisher J.L., Gui J., Hampton T.H., Cote A.L., Ernstoff M.S. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-Oncology 2011, 13:393-400. 10.1093/neuonc/noq204.
228. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 2010, 120:694-705. 10.1172/JCI40283.
229. Chinot O.L., de L.M.Rouge T., Moore N., Zeaiter A., Das A., Phillips H., et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 2011, 28:334-340. 10.1007/s12325-011-0007-3.
230. Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 2014, 370:709-722. 10.1056/NEJMoa1308345.
231. Fine H.A. Bevacizumab in glioblastoma - still much to learn. N. Engl. J. Med. 2014, 370:764-765. 10.1056/NEJMe1313309.
232. Gabrusiewicz K., Liu D., Cortes-Santiago N., Hossain M.B., Conrad C.A., Aldape K.D., et al. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 2014, 5:2208-2220.
233. Gustafson M.P., Lin Y., New K.C., Bulur P.A., O'Neill B.P., Gastineau D.A., et al. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro-Oncology 2010, 12:631-644. 10.1093/neuonc/noq001.
234. Kusmartsev S., Vieweg J. Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nat. Rev. Urol. 2009, 6:540-549. 10.1038/nrurol.2009.177.
235. Fujiwara Y., Komohara Y., Ikeda T., Takeya M. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci. 2011, 102:206-211. 10.1111/j.1349-7006.2010.01772.x.
236. Fujiwara Y., Komohara Y., Kudo R., Tsurushima K., Ohnishi K., Ikeda T., et al. Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3. Oncol. Rep. 2011, 26:1533-1537. 10.3892/or.2011.1454.
237. Fujita M., Zhu X., Sasaki K., Ueda R., Low K.L., Pollack I.F., et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J. Immunol. 2008, 180:2089-2098.
238. Zhu X., Fujita M., Snyder L.A., Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J. Neurooncol. 2011, 104:83-92. 10.1007/s11060-010-0473-5.
239. Debinski W., Choi Y.A., Gibo D.M. Antigens characteristic of M2 type pro-inflammatory macrophages are present on GBM tumor cells. Neuro-Oncology 2013, 15:iii62-iii67. 10.1093/neuonc/not177.
240. Kühnöl C., Herbarth M., Föll J., Staege M.S., Kramm C. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol. Immunother. 2013, 62:1797-1809. 10.1007/s00262-013-1484-9.
241. Mahaweni N.M., Kaijen-Lambers M.E.H., Dekkers J., Aerts J.G.J.V., Hegmans J.P.J.J. Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J. Extracell. Vesicles 2013, 2. 10.3402/jev.v2i0.22492.
242. Cooper D., Bansal-Pakala P., Croft M. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur. J. Immunol. 2002, 32:521-529. 10.1002/1521-4141(200202)32:2<521::AID-IMMU521>3.0.CO;2-X.
243. Cannons J.L., Lau P., Ghumman B., DeBenedette M.A., Yagita H., Okumura K., et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 2001, 167:1313-1324.
244. Yeung Y.T., Bryce N.S., Adams S., Braidy N., Konayagi M., McDonald K.L., et al. p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. J. Neurooncol. 2012, 109:35-44. 10.1007/s11060-012-0875-7.
245. Ji R.-R., Suter M.R. p38 MAPK, microglial signaling, and neuropathic pain. Mol. Pain 2007, 3:1-9. 10.1186/1744-8069-3-33.
246. The human protein atlas (n.d.), (accessed March 31, 2014). http://www.proteinatlas.org/ENSG00000129226/cancer/tissue/glioma.
247. The human protein atlas (n.d.), (accessed March 31, 2014). http://www.proteinatlas.org/ENSG00000169896/cancer/tissue/glioma.